Source BioScience - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Source BioScience

Source BioScience UK storage suite, based in Rochdale, offers 2,000m3 of controlled environment storage space providing pharmaceutical stability storage at all World Climatic ICH conditions as well as bespoke conditions.

Biological storage at low and ultra-low temperatures is available at temperatures from -20°C to -80°C. Our ultra-low temperature facility can store millions of samples, vials or tube racks and annual validation and servicing by our in-house engineers ensures the most reliable storage solution.

Our HTA licensed cryobank uses DryStore freezers for cryogenic storage at -190°C, vapour phase storage systems designed to ensure against sample contamination. Our state of the art biorepository provides secure storage for stem cells, cord stem cells, biological samples, DNA and bone marrow.

We also have IMB certified storage facilities in Tramore, Ireland and storage suites in Kennesaw, near Atlanta, Georgia and Los Angeles,California, USA.

On-site engineers monitor equipment and undertake preventive maintenance with back-up generators providing additional security in the event of power failure.

Our engineers offer a full validation and calibration service using a combination of UKAS (United Kingdom Accreditation Service) calibrated equipment and state-of-the-art data acquisition systems. Qualified and experienced engineers are extensively trained in the validation and calibration of any make/model of environmental chamber as well as our own manufactured product.

Contact details
Source BioScience
John Boyd Dunlop Drive
Kingsway Business Park
Rochdale
UK
Tel: +44 (0)115 973 9012
Email: sales@sourcebioscience.com
Web: storagesolutions.sourcebioscience.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
FindPharma Custom Search

Click here